VERTEX PHARMACEUTICALS INC / MA Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued of $95.70 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued · last filed 2026-02-13
- 2025-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $95.70M.
- 2024-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $82.60M.
- 2023-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $124.10M.
- 2022-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $39.20M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued |
|---|---|
| 2025-12-31 | $95.70M 10-K · filed 2026-02-13 |
| 2024-12-31 | $82.60M 10-K · filed 2026-02-13 |
| 2023-12-31 | $124.10M 10-K · filed 2025-02-13 |
| 2022-12-31 | $39.20M 10-K · filed 2024-02-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-10 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 |
| 2018-12-31 | $0.00 10-K · filed 2019-02-13 |
| 2018-09-30 | $0.00 10-Q · filed 2018-10-25 |
| 2018-06-30 | $0.00 10-Q · filed 2018-07-26 |
| 2018-03-31 | $0.00 10-Q · filed 2018-04-27 |
| 2017-12-31 | $0.00 10-K · filed 2018-02-15 |
| 2017-09-30 | $0.00 10-Q · filed 2017-10-30 |
| 2017-06-30 | $0.00 10-Q · filed 2017-07-28 |
| 2017-03-31 | $0.00 10-Q · filed 2017-04-28 |
| 2016-12-31 | $0.00 10-K · filed 2017-02-23 |
| 2016-09-30 | $0.00 10-Q · filed 2016-10-31 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-01 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-03 |
| 2015-12-31 | $0.00 10-K · filed 2016-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |